Topics

Three reasons the Administration should abandon its International Pricing Index proposal

09:30 EST 31 Jan 2020 | PhRMA

According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American patients losing access to new lifesaving treatments.” By that logic, the Administration’s proposed International Pricing Index (IPI) model should be abandoned immediately.

Original Article: Three reasons the Administration should abandon its International Pricing Index proposal

NEXT ARTICLE

More From BioPortfolio on "Three reasons the Administration should abandon its International Pricing Index proposal"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...